Here we will take a look at the Gross Margin Score of U.S. Stem Cell, Inc. (OTCPK:USRM) shares. The equity currently has a score of 2.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative. The low score of 2.00000 for U.S. Stem Cell, Inc. indicates a top score for stability and growth.
Occasionally, investors may feel like they are riding on a wild roller coaster when dealing with the stock market. Controlling emotions when taking the ride may assist with making necessary decisions when the time comes. Many investors choose to do thorough research when purchasing any stock. Knowing what is owned and why it is owned may help ease the mind when things get sticky. When the market is riding high and there is generally smooth sailing on the investing seas, individual investors may have the tendency to get complacent. Being prepared for any situation may help ease the stress of big market decision making. There may be a time when it seems like everything is going off the rails, but having an actual game plan for management and recovery could make a huge difference both financially and psychologically.
Checking in on some valuation rankings, U.S. Stem Cell, Inc. (OTCPK:USRM) has a Value Composite score of 89. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 94.
After a recent scan, we can see that U.S. Stem Cell, Inc. (OTCPK:USRM) has a Shareholder Yield of -130.888664 and a Shareholder Yield (Mebane Faber) of -22.24673. The first value is calculated by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the firm is giving back to shareholders via a few different avenues. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return.
At the time of writing, U.S. Stem Cell, Inc. (OTCPK:USRM) has a Piotroski F-Score of 5. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.
U.S. Stem Cell, Inc. (OTCPK:USRM) has a current ERP5 Rank of 15829 . The ERP5 Rank may assist investors with spotting companies that are undervalued. This ranking uses four ratios. These ratios are Earnings Yield, ROIC, Price to Book, and 5 year average ROIC. When looking at the ERP5 ranking, it is generally considered the lower the value, the better.
Shifting gears, we can see that U.S. Stem Cell, Inc. (OTCPK:USRM) has a Q.i. Value of 50.00000. The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield. The purpose of the Q.i. Value is to help identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the company tends to be.